Failure of lithium to reduce period of neutropenia during induction therapy of acute myeloid leukemia

Hematological Oncology
J H Scarffe, J Chang

Abstract

Fifty-four patients treated with daunorubicin, cytosine arabinoside and thioquanine for acute myeloid leukemia were randomly assigned to receive oral lithium carbonate 1200 mg daily or no lithium. The duration of neutropenia (less than 0.5 x 10(9)/L) was similar between controls (median 22.5 days) and patients treated with lithium (median 24 days). The number of remissions, relapse-free survival and survival were similar for the lithium treated and control groups of patients. There was no apparent clinical efficacy in the use of lithium to reduce the period of neutropenia in patients undergoing remission induction therapy for acute myeloid leukemia.

References

Jun 18, 1977·Lancet·D CharronL Degos
Feb 24, 1979·Lancet·L E Orr, J F McKernan
Jan 26, 1978·The New England Journal of Medicine·G RothsteinJ W Athens
Aug 25, 1977·The New England Journal of Medicine·R S SteinH G Jume'an
Apr 23, 1983·Lancet·G Resek, S Olivieri
Jul 1, 1982·British Journal of Haematology·C E Gauwerky, D W Golde
Jan 1, 1984·Medical and Pediatric Oncology·R C HornsP L Greenberg
Jan 1, 1980·Advances in Experimental Medicine and Biology·D J CharronL Degos

❮ Previous
Next ❯

Citations

Oct 1, 1991·British Journal of Haematology·M R RansonD Ryder
Jun 16, 2009·Cell Transplantation·Wise Young
Sep 1, 1991·DICP : the Annals of Pharmacotherapy·N Volf, M L Crismon

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.